NO:24, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:36, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:56, SEQ ID NO:60, or SEQ ID NO:64.

- 24. (New) The polypeptide of claim 22, wherein the functional variant of the V_H region is SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:38, SEQ ID NO:42, SEQ ID NO:46, SEQ ID NO:50, SEQ ID NO:54, or SEQ ID NO:62.
- 25. (New) The polypeptide of claim 22, wherein the polypeptide is an antigen binding Rab fragment.
- 26. (New) The polypeptide of claim 22, wherein the polypeptide is an immunoglobulin specific for a Rhesus D antigen.
- 27. (New) The polypeptide of claim 26, wherein the immunoglobulin comprises at least one of the defined isotypes selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.
- 28. (New) A recombinant polynucleotide which encodes the polypeptide of claim 22.
- 29. (New) A pharmaceutical composition comprising at least one polypeptide of claim 22.
- 30. (New) A pharmaceutical composition comprising at least one immunoglobulin of claim 26.
- 31. (New) A diagnostic composition for Rhesus D typing comprising at least one polypeptide of claim 22.
 - 32. (New) A diagnostic composition for Rhesus D typing

comprising at least one antibody of claim 26.

- 33. (New) A purified polypeptide capable of forming antigen binding atructures with specificity for Rhesus D antigens comprising a V_H region and a V_L region having SEQ ID NO:60 or a functional variant thereof.
- 34. (New) The polypeptide of claim 33, wherein the $V_{\scriptscriptstyle H}$ region is SEQ ID NO:2 SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:18, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:38, SEQ ID WO:42, SEQ ID NO:46, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:58, or SEQ ID NO:62.
- 35. (New) The polypeptide of claim 33, wherein the functional variant of the V_L region is SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:36, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:52, SEQ ID NO:56, or SEQ ID NO:64.
- 36. (New) The polypeptide of claim 33, wherein the polypeptide is an antigen binding Fab fragment.
- 37. (New) The polypeptide of claim 33, wherein the polypeptide is an immunoglobulin specific \for a Rhesus D antigen.
- 38. (New) The polypeptide of claim 37, wherein the immunoglobulin comprises at least one of the defined isotypes selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.
- 39. (New) A recombinant polynicleotide which encodes the polypeptide of claim 33.
 - 40. (New) A pharmaceutical composition comprising at least one

polypeptide of claim 33.

41 (New) A pharmaceutical composition comprising at least one antibody of claim 33.

- 42. (New) A diagnostic composition for Rhesus D typing comprising at least one polypeptide of claim 33.
- 43. (New A diagnostic composition for Rhesus D typing comprising at least one antibody of claim 33.
- 44. (New) A method for preventing or treating a hematologic disorder in a subject comprising administering to the subject a pharmaceutical composition comprising at least one of the following
 - (a) a purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens comprising a $V_{\rm H}$ region having SEQ ID NO:58 or a functional variant thereof and a $V_{\rm L}$ region;
 - (b) a purified polypeptide capable of forming antigen binding structures with specificity for Rhesus D antigens comprising a V_R region and a V_L region having SEQ ID NO:60 or a functional variant thereof;
 - (c) an immunoglobulin specific for a Rhesus D antigen comprising a purified polypeptide having a V_H region having SEQ ID NO:58 or a functional variant thereof and a V_L region; or
 - (d) an immunoglobulin specific for a Rhesus D antigen comprising a purified polypeptide having a V_H region and a V_L region having SEQ ID NO:60 or a functional variant thereof;

wherein the hematologic disorder is haemolytic disease of the newborn (HDN), immune thrombocytopenic purpura (ITP), or mistransfusion of Rhesus incompatible blood.

FI

[7]